Drug Profile
OCU 410
Alternative Names: AAV-RORA; OCU-410Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Schepens Eye Research Institute
- Developer Ocugen
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Dry age-related macular degeneration
Most Recent Events
- 05 Apr 2024 Adverse events data from a phase I/II trial in Dry age-related macular degeneration released by Ocugen
- 23 Aug 2023 Phase-I/II clinical trials in Dry age-related macular degeneration in USA (Subretinal) (NCT06018558)
- 21 Aug 2023 The US FDA approves IND application for OCU 410 in Dry-macular degeneration